Close Menu

NEW YORK — Centogene last week filed to go public in the US through an offering of up to $69 million of its common stock.

In its filing with the US Securities and Exchange Commission, however, Centogene noted that it has not finalized the number of shares it intends to offer or the price per share.

SVB Leerink and Evercore ISI are listed in the filing as the underwriters for the IPO.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.